OncoQuest Pharmaceuticals Inc Cash Flow Conversion Efficiency
OncoQuest Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, OncoQuest Pharmaceuticals Inc (078590) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.42 Billion ≈ $-964.13K USD) by net assets (₩74.92 Billion ≈ $50.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OncoQuest Pharmaceuticals Inc (2014–2025)
Cash flow conversion efficiency of OncoQuest Pharmaceuticals Inc from 2014 to 2025. This chart illustrates how OncoQuest Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OncoQuest Pharmaceuticals Inc (078590) share price today for real-time trading data and today's change.
OncoQuest Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
OncoQuest Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OncoQuest Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OncoQuest Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see OncoQuest Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dimerix Ltd
AU:DXB
|
3.087x |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
-1.034x |
|
AMTD IDEA Group
NYSE:AMTD
|
0.003x |
|
Cellectis SA
NASDAQ:CLLS
|
-0.348x |
|
AnaPass Inc
KQ:123860
|
-0.004x |
|
Neuraxis, Inc.
NYSE MKT:NRXS
|
-0.214x |
|
DT Cloud Star Acquisition Corporation Units
NASDAQ:DTSQU
|
-0.001x |
|
TIAN GE INT.HLDGS DL-0001
F:04T
|
N/A |
Annual Cash Flow Conversion Efficiency for OncoQuest Pharmaceuticals Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of OncoQuest Pharmaceuticals Inc from 2014 to 2025. Review cash generation quality of OncoQuest Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩48.94 Billion ≈ $33.17 Million |
₩485.35 Million ≈ $328.91K |
0.010x | -88.00% |
| 2024-12-31 | ₩47.92 Billion ≈ $32.47 Million |
₩3.96 Billion ≈ $2.68 Million |
0.083x | -67.92% |
| 2023-12-31 | ₩43.42 Billion ≈ $29.43 Million |
₩11.19 Billion ≈ $7.58 Million |
0.258x | +3873.45% |
| 2022-12-31 | ₩34.70 Billion ≈ $23.51 Million |
₩-236.91 Million ≈ $-160.55K |
-0.007x | +96.04% |
| 2019-12-31 | ₩24.71 Billion ≈ $16.74 Million |
₩-4.26 Billion ≈ $-2.89 Million |
-0.172x | -413.09% |
| 2018-12-31 | ₩26.14 Billion ≈ $17.71 Million |
₩1.44 Billion ≈ $975.22K |
0.055x | -80.11% |
| 2017-12-31 | ₩17.32 Billion ≈ $11.73 Million |
₩4.79 Billion ≈ $3.25 Million |
0.277x | +11.73% |
| 2016-12-31 | ₩14.30 Billion ≈ $9.69 Million |
₩3.54 Billion ≈ $2.40 Million |
0.248x | +6.21% |
| 2015-12-31 | ₩11.98 Billion ≈ $8.12 Million |
₩2.79 Billion ≈ $1.89 Million |
0.233x | +63.10% |
| 2014-12-31 | ₩7.10 Billion ≈ $4.81 Million |
₩1.02 Billion ≈ $688.18K |
0.143x | -- |
About OncoQuest Pharmaceuticals Inc
DIAC Co., Ltd. engages in the car interior and exterior materials business in South Korea and internationally. DIAC Co., Ltd. was founded in 1993 and is headquartered in Miryang-si, South Korea.